HuLA immune(フライミューン)株式会社は、患者さんに笑顔になっていただくことを使命にした大阪大学発のバイオベンチャーです

HuLA immune(フライミューン株式会社)へはお気軽にお問い合わせ下さい

Technology

Key Technology

Key Technologyイメージ

Our novel medicines created by applying the “Neo-Self” theory advocated by Dr. Arase antibodies not only inhibit pathogenic signal transduction in vitro via both T cells and B cells involved in the onset and progression of autoimmune diseases, but also ameliorate pathological conditions of autoimmune diseases in several vivo mouse models. (http://immchem.biken.osaka-u.ac.jp/

We are developing the medicines in several autoimmune diseases in response to unmet medical needs.

In regard to APS, we are also developing a new diagnostic agent applied by the ”Neo-Self” theory to solve diagnostic problems.

References

  • Arase, H. 2015. Rheumatoid Rescue of Misfolded Cellular Proteins by MHC Class II Molecules: A New Hypothesis for Autoimmune Diseases Adv. Immunol.
    129:1-23.
  • Arase, N., Arase, H. 2015. Cellular misfolded proteins rescued from degradation by MHC class II molecules are possible targets for autoimmune diseases. J.
    Biochem. 158:367-372.

当社では「ヒト細胞を用いた研究」を適正に実施するため、国の基本指針(「人を対象とする医学系研究に関する倫理指針」等)に基づき、
研究倫理審査員会を設置し、各研究計画の倫理的及び科学的妥当性を厳正に審議しております。

委員会規則や委員会名簿及び議事の概要などは、厚生労働省の倫理委員会報告システムを通じて公表します。